Merck: returns to profit in Q2
(CercleFinance.com) - Merck announces that sales reached $16.
1bn in Q2, up 7% y-o-y. Sales were notably driven by a 16% increase in Keytruda sales, to $7.3bn.
The company posted adjusted net income of $5.8bn, a far cry from the $5.2bn loss recorded in Q2 2023. Adjusted EPS thus rises from -$2.06 twelve months ago to +$2.28.
Our business showed strong momentum at the end of H1 Merck said, adding that thanks to excellent scientific, commercial and operational execution, it is achieving important milestones for the company and patients alike.
Merck is targeting FY worldwide sales of $63.4bn to $64.4bn, and adjusted EPS of $8.94 to $8.04.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
1bn in Q2, up 7% y-o-y. Sales were notably driven by a 16% increase in Keytruda sales, to $7.3bn.
The company posted adjusted net income of $5.8bn, a far cry from the $5.2bn loss recorded in Q2 2023. Adjusted EPS thus rises from -$2.06 twelve months ago to +$2.28.
Our business showed strong momentum at the end of H1 Merck said, adding that thanks to excellent scientific, commercial and operational execution, it is achieving important milestones for the company and patients alike.
Merck is targeting FY worldwide sales of $63.4bn to $64.4bn, and adjusted EPS of $8.94 to $8.04.
Copyright (c) 2024 CercleFinance.com. All rights reserved.